文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌放疗后局部复发再程HDR样SBRT的疗效与毒性

Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-10-17

单中心回顾性研究纳入50例放疗后>2年活检证实局部复发的前列腺癌患者,再程给予3400 cGy/5次HDR样SBRT。中位随访44个月,5年生化无病生存率60%,局部控制率94%,≥3级泌尿毒性8%,无>1级胃肠道毒性。

要点

  • 再程HDR样SBRT后5年生化无病生存率60%,局部控制率94%。
  • 再程前PSA<6.92 ng/mL者5年生化无病生存率78%,≥6.92 ng/mL者仅12%。
  • ≥3级泌尿毒性5年发生率8%,限于既往仅常规外照射者3%,无>1级胃肠道毒性。

核心结论

  • 对既往放疗后局部复发的前列腺癌,再程HDR样SBRT临床可行,PSA和DFS应答良好,可将挽救性雄激素剥夺治疗或其他治疗需求推迟超过5年,泌尿和胃肠道毒性低。

研究设计与样本

  • 2009至2018年单中心50例活检证实放疗后>2年前列腺局部复发患者,再程给予3400 cGy/5次HDR样SBRT,既往放疗剂量75.6 Gy(64.8-81.0),中位挽救间隔8.1年(32-241个月)。

主要发现

  • 中位随访44个月(3-110),非复发患者PSA中位值从再程前3.97 ng/mL降至1年0.6 ng/mL和5年0.16 ng/mL。
  • 5年 actuarial 生化无病生存率60%,5年局部、远处和免于挽救性ADT率分别为94%、89%和69%。
  • 再程前PSA<6.92 ng/mL者5年生化无病生存率78%,≥6.92 ng/mL者12%(P = .0001)。
  • 毒性主要在泌尿域,5年≥3级 actuarial 发生率8%,限于既往仅常规外照射局部复发者为3%;无>1级胃肠道毒性。
  • 再程时30%患者保持性功能,其中82%后续丧失性功能。

关键数值与推荐

  • 再程SBRT剂量3400 cGy分5次,计划靶区为临床靶区(前列腺+仅连续延伸)无额外外扩。
  • 既往放疗剂量中位75.6 Gy(64.8-81.0),再程前排除既往毒性>1级者。
  • 毒性评估采用CTCAE v.3.0标准。

临床怎么用

  • 对既往放疗后>2年活检证实局部复发且既往毒性≤1级的前列腺癌患者,可考虑再程HDR样SBRT 3400 cGy/5次。
  • 再程前PSA<6.92 ng/mL者生化无病生存率显著更高,患者选择时可参考该指标。
  • 再程时性功能保留者需告知再程后82%可能丧失性功能。

局限性

  • 单中心回顾性研究,样本量50例,中位随访44个月。
  • 排除既往毒性>1级者,结果可能不适用于该人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the use of high dose-rate-like stereotactic body radiation therapy (SBRT) retreatment for biopsy-proven local persistence in prostate postradiation therapy, evaluating efficacy and toxicity. METHODS AND MATERIALS: From 2009 to 2018, 50 patients with biopsy-proven recurrent prostate cancer >2 years after prior treatment were retreated with a high dose-rate-like dose of 3400 cGy over 5 fractions. Previous radiation therapy dose measured 75.6 Gy (64.8-81.0) and median salvage interval was 8.1 years (32-241 mo.). Eighty-three percent of patients had Gleason score 7 or higher disease at retreatment. Those with preexisting toxicity >grade 1 from their prior course were excluded. The planning target volume was comprised of the clinical target volume (prostate + any contiguous extension only) with no additional expansion. Toxicity assessment used CTCAE v.3.0 criteria. RESULTS: Median follow-up was 44 months (3-110). Median pre-SBRT salvage baseline prostate specific antigen (PSA) of 3.97 ng/mL decreased to 0.6 ng/mL and 0.16 ng/mL at 1 and 5 years in nonrelapsed patients, respectively. Actuarial 5-year biochemical disease-free survival (DFS) measured 60%, with corresponding 5-year actuarial local, distant, and salvage androgen deprivation therapy free rates of 94%, 89%, and 69%, respectively. Actuarial 5-year biochemical DFS measured 78% if PSA at salvage was <6.92 ng/mL versus 12% with ≥6.92 ng/mL (P = .0001). Toxicity was primarily in the GU domain, with an 8% 5-year actuarial rate of grade 3+, 3% when limited to salvage of "conventional external beam only" local relapse. No gastrointestinal (GI) toxicity >grade 1 occurred. Of the 30% sexually potent at the time of salvage, 82% subsequently lost potency. CONCLUSIONS: SBRT salvage of local prostate recurrence in previously irradiated patients appears clinically feasible in this challenging group. It demonstrates favorable PSA and DFS response, typically deferring the need for salvage androgen deprivation therapy or other treatment by over 5 years, with low GU and GI toxicity.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Fuller D, Wurzer J, Shirazi R, et al. Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT. Int J Radiat Oncol Biol Phys. 2019. PMID: 31629838. doi:10.1016/j.ijrobp.2019.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。